# Regency Centers Corp: financial statements, quarterly

REG · Nasdaq · CIK 910606 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/reg.md) · [Financials](/companies/reg/financials.md) · [Filings](/companies/reg/filings.md) · [Insiders](/companies/reg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/reg/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q2 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [314](/filings/0000950170-24-089720.md) | [331](/filings/0000950170-24-120019.md) | [360 d](/filings/0001193125-26-051668.md) | [364](/filings/0000950170-25-062596.md) | [357](/filings/0000950170-25-101867.md) | [360](/filings/0001193125-25-266456.md) | [373 d](/filings/0001193125-26-051668.md) | [381](/filings/0001193125-26-203537.md) | [381](/filings/0000950170-25-101867.md) | [388](/filings/0001193125-25-266456.md) | [404 d](/filings/0001193125-26-051668.md) | [412](/filings/0001193125-26-203537.md) |
| Operating income | $m | not reported | not reported | not reported | [263](/filings/0000950170-25-062596.md) | [258](/filings/0000950170-25-101867.md) | [261](/filings/0001193125-25-266456.md) | [265 d](/filings/0001193125-26-051668.md) | [274](/filings/0001193125-26-203537.md) | [281](/filings/0000950170-25-101867.md) | [282](/filings/0001193125-25-266456.md) | [287 d](/filings/0001193125-26-051668.md) | [296](/filings/0001193125-26-203537.md) |
| Interest expense | $m | [37.0](/filings/0000950170-23-038453.md) | [38.8](/filings/0000950170-23-059213.md) | [42.1 d](/filings/0000950170-24-016260.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [86.8](/filings/0000950170-24-089720.md) | [90.7](/filings/0000950170-24-120019.md) | [89.8 d](/filings/0001193125-26-051668.md) | [110](/filings/0000950170-25-062596.md) | [103](/filings/0000950170-25-101867.md) | [101](/filings/0001193125-25-266456.md) | [86.5 d](/filings/0001193125-26-051668.md) | [110](/filings/0001193125-26-203537.md) | [106](/filings/0000950170-25-101867.md) | [109](/filings/0001193125-25-266456.md) | [202 d](/filings/0001193125-26-051668.md) | [129](/filings/0001193125-26-203537.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:Revenues
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: not reported

## Balance sheet

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q2 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $bn | [10.8](/filings/0000950170-23-038453.md) | [12.4](/filings/0000950170-23-059213.md) | [12.4](/filings/0000950170-25-021359.md) | [12.7](/filings/0000950170-24-052749.md) | [12.4](/filings/0000950170-24-089720.md) | [12.4](/filings/0000950170-24-120019.md) | [12.4](/filings/0001193125-26-051668.md) | [12.6](/filings/0000950170-25-062596.md) | [12.7](/filings/0000950170-25-101867.md) | [13.1](/filings/0001193125-25-266456.md) | [13.0](/filings/0001193125-26-203537.md) | [13.0](/filings/0001193125-26-203537.md) |
| Total liabilities | $bn | [4.7](/filings/0000950170-23-038453.md) | [5.1](/filings/0000950170-23-059213.md) | [5.2](/filings/0000950170-25-021359.md) | [5.5](/filings/0000950170-24-052749.md) | [5.4](/filings/0000950170-24-089720.md) | [5.5](/filings/0000950170-24-120019.md) | [5.5](/filings/0001193125-26-051668.md) | [5.7](/filings/0000950170-25-062596.md) | [5.9](/filings/0000950170-25-101867.md) | [6.0](/filings/0001193125-25-266456.md) | [5.8](/filings/0001193125-26-203537.md) | [5.9](/filings/0001193125-26-203537.md) |
| Long-term debt | $bn | [3.7](/filings/0000950170-23-038453.md) | [4.1](/filings/0000950170-23-059213.md) | [4.2](/filings/0000950170-25-021359.md) | [4.4](/filings/0000950170-24-052749.md) | [4.4](/filings/0000950170-24-089720.md) | [4.4](/filings/0000950170-24-120019.md) | [4.4](/filings/0001193125-26-051668.md) | [4.6](/filings/0000950170-25-062596.md) | [4.8](/filings/0000950170-25-101867.md) | [4.9](/filings/0001193125-25-266456.md) | [4.7](/filings/0001193125-26-203537.md) | [5.0](/filings/0001193125-26-203537.md) |
| Shareholders' equity | $bn | [6.0](/filings/0000950170-23-038453.md) | [7.1](/filings/0000950170-23-059213.md) | [7.0](/filings/0000950170-25-021359.md) | [7.0](/filings/0000950170-24-052749.md) | [6.8](/filings/0000950170-24-089720.md) | [6.8](/filings/0000950170-24-120019.md) | [6.7](/filings/0001193125-26-051668.md) | [6.7](/filings/0000950170-25-062596.md) | [6.7](/filings/0000950170-25-101867.md) | [6.8](/filings/0001193125-25-266456.md) | [6.9](/filings/0001193125-26-203537.md) | [6.9](/filings/0001193125-26-203537.md) |

- Cash and equivalents: not reported
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [173 d](/filings/0000950170-24-089720.md) | [213 d](/filings/0000950170-24-120019.md) | [172 d](/filings/0001193125-26-051668.md) | [168](/filings/0000950170-25-062596.md) | [203 d](/filings/0000950170-25-101867.md) | [228 d](/filings/0001193125-25-266456.md) | [191 d](/filings/0001193125-26-051668.md) | [161](/filings/0001193125-26-203537.md) | [244 d](/filings/0000950170-25-101867.md) | [219 d](/filings/0001193125-25-266456.md) | [204 d](/filings/0001193125-26-051668.md) | [153](/filings/0001193125-26-203537.md) |
| Dividends paid | $m | [111 d](/filings/0000950170-24-089720.md) | [110 d](/filings/0000950170-24-120019.md) | [120 d](/filings/0001193125-26-051668.md) | [124](/filings/0000950170-25-062596.md) | [124 d](/filings/0000950170-25-101867.md) | [122 d](/filings/0001193125-25-266456.md) | [121 d](/filings/0001193125-26-051668.md) | [128](/filings/0001193125-26-203537.md) | [128 d](/filings/0000950170-25-101867.md) | [128 d](/filings/0001193125-25-266456.md) | [128 d](/filings/0001193125-26-051668.md) | [276](/filings/0001193125-26-203537.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-24-089720.md) | [0.0 d](/filings/0000950170-24-120019.md) | [0.0 d](/filings/0001193125-26-051668.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-266456.md) | [0.0 d](/filings/0001193125-26-051668.md) | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2018-06-30) | period not labelled (2018-09-30) | period not labelled (2019-03-31) | Q2 FY2019 (2019-06-30) | Q3 FY2019 (2019-09-30) | Q1 FY2020 (2020-03-31) | Q2 FY2020 (2020-06-30) | Q3 FY2020 (2020-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [170](/filings/0001564590-19-029450.md) | [170](/filings/0001564590-19-039836.md) | [168](/filings/0001564590-20-023379.md) | [168](/filings/0001564590-20-035935.md) | [168](/filings/0001564590-20-051795.md) | [168](/filings/0001564590-20-023379.md) | [170](/filings/0001564590-20-035935.md) | [170](/filings/0001564590-20-051795.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 183,096,790 at 2026-04-30, from the cover of the [10-Q filed 2026-05-04](/filings/0001193125-26-203537.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.